CN101653504A - Traditional Chinese medicine for treating depression - Google Patents
Traditional Chinese medicine for treating depression Download PDFInfo
- Publication number
- CN101653504A CN101653504A CN200910084301A CN200910084301A CN101653504A CN 101653504 A CN101653504 A CN 101653504A CN 200910084301 A CN200910084301 A CN 200910084301A CN 200910084301 A CN200910084301 A CN 200910084301A CN 101653504 A CN101653504 A CN 101653504A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- parts
- weight portion
- medicine preparation
- traditional chinese
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a traditional Chinese medicine for treating depression, which is prepared by the following traditional Chinese medicine raw materials in parts by weight: 10-14 parts of longanfruit, 10-14 parts of fried jujube kernels, 8-12 parts of polygalae, 8-12 parts of platycladi seed, 3-7 parts of radix glycyrrhizae preparata, 8-12 parts of ginseng, 10-14 parts of astragalus root, 13-17 parts of tuckahoe, 10-14 parts of atractylodis and 8-12 parts of angelica. The traditional Chinese medicine features good antidepressive therapeutic effect, little adverse reaction, slight degree,few side effects, good tolerability and high compliance of patients during drug administration.
Description
Technical field
The present invention relates to a kind of Chinese medicine preparation that is used for the treatment of depression, more precisely is the Chinese medicine preparation that depression is just sent out in treatment.
Background technology
Depression is a kind of common frdquently encountered disease, and World Health Organization's statistics patients with depression accounts for the 3-5% of whole world population, is equivalent to 1.2-2 hundred million people.In western countries such as the U.S., Germany, 10% resident has depressed tendency.And in country and area underdeveloped, the population ratio that has the depression dominant character is higher, and some are local even reached 20%.Message from psychiatric department branch of Chinese doctors'associations shows: the present patients with depression of China has 3,000 ten thousand approximately.
Because of all burdens that depression brought make the whole world all can lose the output value of 2%-5% every year, add up according to World Health Organization (WHO), with regard to the disease burden, depression has become the fourth-largest disease in the world at present, and expecting the year two thousand twenty may will become the human second largest illness that is only second to cardiovascular disease.
Depression is as the more and more outstanding mental illness of society, and numerous medicines have curative effect preferably to depression, but in clinical practice, various untoward reaction appear in Western medicine inevitably, as has xerostomia, blurred vision, memory dysfunction etc.Although in recent years, because pharmaceutical technology is constantly reformed, the side reaction of the antidepressant drug of a new generation reduces, but part patient still certain untoward reaction can occur, influence the compliance of patient treatment, even be forced to therapy discontinued for this reason, and therefore seek the medicine of treatment by Chinese herbs depression with Chinese quintessence of Chinese culture, be the common hope of pursuing of doctor and patient.
Summary of the invention
At above-mentioned situation, the purpose of this invention is to provide a kind of Chinese medicine preparation for the treatment of depression, especially the Chinese medicine preparation of depression is just sent out in treatment, can effectively treat and just send out depression, and side effect can be dropped to minimum.
To achieve these goals, the present invention adopts Arillus Longan, Semen Ziziphi Spinosae (parched), Radix Polygalae, Semen Platycladi, Radix Glycyrrhizae Preparata, Radix Ginseng, the Radix Astragali, Poria, the Rhizoma Atractylodis Macrocephalae, the Radix Angelicae Sinensis reasonable compatibility, be processed into the Chinese medicine preparation for the treatment of depression through science, the weight portion proportioning is respectively: Arillus Longan 10-14 weight portion, Semen Ziziphi Spinosae (parched) 10-14 weight portion, Radix Polygalae 8-12 weight portion, Semen Platycladi 8-12 weight portion, Radix Glycyrrhizae Preparata 3-7 weight portion, Radix Ginseng 8-12 weight portion, Radix Astragali 10-14 weight portion, Poria 13-17 weight portion, Rhizoma Atractylodis Macrocephalae 10-14 weight portion, Radix Angelicae Sinensis 8-12 weight portion.
Described Chinese medicine preparation is a said dosage form on any materia medica.
Described dosage form is a capsule, tablet, granule, oral liquid, pill, powder, sublimed preparation, any pharmaceutical dosage form in the unguentum.
Beneficial effect of the present invention is:
Antidepressant good effect of the present invention, untoward reaction is few, and side effect is little.Patient take medicine better tolerance, compliance height.
The specific embodiment
Below in conjunction with embodiment and practical situation the present invention is elaborated.
The prescription requirement according to the present invention, in weight portion proportioning Arillus Longan 10, Semen Ziziphi Spinosae (parched) 10, Radix Polygalae 8, Semen Platycladi 8, Radix Glycyrrhizae Preparata 3, Radix Ginseng 8, the Radix Astragali 10, Poria 13, the Rhizoma Atractylodis Macrocephalae 10 Radix Angelicae Sinensis 8 are mixed and made into Chinese medicine preparation.
In above-mentioned prescription with the sweet temperature compensation spleen QI invigorating of ginseng stilbene art grass; The sweet hot replenishing vital QI with drugs of warm nature liver of Radix Angelicae Sinensis and give birth to painstaking effort, Arillus Longan, Poria, Semen Ziziphi Spinosae (parched) tranquilizing by nourishing the heart, Radix Polygalae restoring normal coordination between the heart and kidney and the sedate mind calming goes the Radix Aucklandiae to add Semen Platycladi to strengthen the merit of tranquilizing by nourishing the heart.Above-mentioned science compatibility can reach the effect of the spleen invigorating of nourishing heart, benefiting QI and nourishing blood jointly, thereby makes depression be able to effective treatment.
Below the effect of mouse experiment and clinical practice treatment depression has all been obtained fully proving.
The pharmacodynamics pharmacological toxicology is learned situation
According to bureau of drug administration of People's Republic of China (PRC) new drug research guideline, show that after deliberation changing Chinese medicine preparation has inhibitory action to nervus centralis, the appropriate sleeping number of subliminal hypnosis dosage of receiving of experiment mice penta crust is obviously increased, the sleep time-lag action is arranged.Show through animal acute toxicity test, be equivalent to 300 times of people's clinical application amount with this Chinese medicine preparation suspension to mouse stomach, mice does not have movable unusual, does not more see death, so as safe as a house during this Chinese medicine preparation oral administration.This Chinese medicine preparation long term toxicity test studies show that this Chinese medicine preparation does not have influence to the normal growth growth of rat, and the every index of hemogram checking is all in normal range, and this Chinese medicine preparation has no adverse effects to the hemopoietic function of rat, does not damage hepatic and renal function.The all no abnormal pathologic of main organs pathological examination changes, and illustrates that this Chinese medicine preparation is very safe.
In order further to estimate the clinical efficacy of this Chinese medicine preparation, 58 routine depressive patients are observed, and to establish venlafaxine be matched group that the observation of system has been carried out in its curative effect, safety and side effect, and situation is as follows:
1, alternative
1.1 go into the group standard: the person that just sends out the depression, its Chinese drugs agentia group 31 examples, male 15 examples, women 16 examples, year mean age (22.69 ± 18.45), course of disease 2-18 month, average (8.55 ± 6.71) individual month; Venlafaxine group 27 examples, male's 12 examples, women's 15 examples, year mean age (25.76 ± 16.90), the course of disease 3～24 months, average (8.85 ± 9.75) individual month.Age, sex, the equal difference not statistically significant of the course of disease between two groups.Meet CCMD-3 about the depression diagnostic criteria; Hamilton depressive scale 17＞17 minutes; Do not have serious physical disease, lab testing is normal, and electrocardiogram is normal.
2, the administrated method and the course of treatment
2.1 treatment
Oral this Chinese drugs agentia of this Chinese drugs agentia group, preparation is a Chinese medicinal granule, each 1 bag (20g), every day 2 (each 1 time sooner or later), totally 6 weeks; The control group venlafaxine (Tianjin Medicine Research Academy Pharmaceutical Co., Ltd's production), initial dose is 25mg, 3 times/d, dosage escalation is to more than the 100mg/d, later on according to the state of an illness and the side reaction size dosage that successively decreases, dosage 100～250mg/d obeyed for 6 weeks altogether, nonjoinder other drug treatment during the treatment.
2.2 statistical method adopts t check and x2 check.
3, result
3.1 criterion of therapeutical effect and efficacy result HAMD subtract branch rate 〉=75% for curing, 74%-50% is marked improvement, and 49%-25% is for progressive, and＜25% is invalid.Chinese medicine preparation group: cure 12 examples (38.71%), marked improvement 10 examples (32.26%), progressive 7 examples (22.58%), invalid 2 examples (6.45%); Venlafaxine group: cure 10 examples (37.04%), marked improvement 10 examples (37.04%), progressive 6 examples (22.22%), invalid 1 example (3.70%).Curative effect difference not statistically significant (P＞0.05) sees Table 1 between two groups.
Table 1 liang group patient Comparison of therapeutic
| Group | The example number | Recovery from illness (%) | Show into (%) | Progressive (%) | Invalid (%) |
| The Chinese medicine preparation group | ??31 | ??12(38.71) | ??10(32.26) | ??7(22.58) | ??2(6.45) |
| The Wan Lafaxin group | ??27 | ??10(37.04) | ??10(37.04) | ??6(22.22) | ??1(3.70) |
2.2 between two groups before and after the patient treatment HAMD scoring relatively HAMD scale score value is from all significantly descending before the treatment in two groups of the 2nd weeks, HAMD marks and compares the equal not statistically significant of its difference and see Table 2 before and after the treatment.And subtract the poor different not statistically significant of branch between Chinese medicine preparation group and venlafaxine group.
Elder sister MD evaluation (example) before and after the table 2 liang group patient treatment
| Treatment time | Chinese medicine preparation group (22) | Wan Lafaxin organizes (19) |
| Before the treatment | ??33.82±9.47 | ??35.69±10.00 |
| 14 days | ??27.63±9.78 | ??27.80±11.77 |
| 28 days | ??14.79±8.34 | ??15.49±8.71 |
| 42 days | ??10.14±6.07 | ??9.02±7.89 |
Annotate: with compare P＜0.05 before the treatment; With the treatment before compare P＜0.01
2.3 untoward reaction comparison Chinese medicine preparation group has 2 examples slight xerostomia to occur, 1 routine mild nausea, and it is dizzy that 1 example is slight, but can both adhere to treatment, accounts for 12.90%; And the venlafaxine group has 14 examples and in various degree untoward reaction occur, accounts for 51.85%, be anxiety, insomnia, headache successively, feel sick, loss of appetite etc.Difference has statistical significance (P＜0.01) between two groups.Liver function between two groups, electrocardiogram, routine blood test etc. are all in normal range.
2.4 the preceding two groups of conditions of patients orders of severity of contrast therapy (SI) and treatment back curative effect general comment (GI) comparing difference not statistically significant are estimated in clinical overall treatment between two groups.Because the untoward reaction of venlafaxine is obviously more than the Chinese medicine preparation group, so the therapeutic index of Chinese medicine preparation group (EI) significantly sees Table 3 for high (P＜0.05) than matched group.
Table 3 liang group patient cGI relatively
| Group | The example number | ??SI | ??GI | ??EI |
| The Chinese medicine preparation group | ??31 | ??4.75±1.21 | ??3.40±0.77 | ??3.09±0.98 |
| The Wan Lafaxin group | ??27 | ??5.12±1.14 | ??3.11±0.74 | ??2.00±1.13 |
Annotate: compare P＜0.01 for two groups
3, conclusion
The present invention just sends out a patients with depression and has tangible antidepressant curative effect treating, and imitate for the purpose of using for the 2nd week, and untoward reaction is low.From theory of Chinese medical science, this Chinese medicine preparation is made up of Arillus Longan, Semen Ziziphi Spinosae (parched), Radix Polygalae, Semen Platycladi, Radix Glycyrrhizae Preparata, Radix Ginseng, the Radix Astragali, Poria, the Rhizoma Atractylodis Macrocephalae, Radix Angelicae Sinensis etc., this Chinese medicine preparation has the effect of vigorate qi and replenish the blood, spleen-benefiting mind-tranquilizing, and this side cures mainly deficiency of both the heart and spleen disease.Heart storing spirit and main blood, the spleen master thinks and system blood.Excessive thinking, impairment caused by overstrain heart spleen, temper is lost empty, painstaking effort secretly consume, then see cardiopalmus, palpitation with a distress feeling, forgetful, be insomnia, anorexia is weak, complexion is not flourish, pale tongue, thready and moderate pulse is all resembling of insufficiency of vital energy and blood.Control and work as vigorate qi and replenish the blood, spleen-benefiting mind-tranquilizing.In this Chinese medicine preparation with the sweet temperature compensation spleen QI invigorating of ginseng stilbene art grass; The sweet hot replenishing vital QI with drugs of warm nature liver of Radix Angelicae Sinensis and give birth to painstaking effort, Arillus Longan, Poria, Semen Ziziphi Spinosae (parched) tranquilizing by nourishing the heart, Radix Polygalae restoring normal coordination between the heart and kidney and the sedate mind calming goes the Radix Aucklandiae to add Semen Platycladi to strengthen the merit of tranquilizing by nourishing the heart.So this Chinese medicine preparation be nourish heart spleen invigorating, benefiting QI and nourishing blood melt side mutually, the QI and blood foot, refreshing from peace, so depression is had therapeutical effect.
From the neurotransmitter theory, this Chinese medicine preparation has the blocking-up norepinephrine reuptake or strengthens the transmission of noradrenaline rope, the reuptake of blocking 5-hydroxytryptamine or inhibition monoamine oxidase, MAO, thereby suppress medicine inactivations such as noradrenaline rope, 5-hydroxy tryptamine, cause that norepinephrine in the synaptic space, 5-hydroxy tryptamine concentration raise.
Antidepressant curative effect of the present invention certainly, untoward reaction is few, degree is light, side effect is little, patient's better tolerance of taking medicine, compliance height.
Claims (3)
1, a kind of Chinese medicine preparation for the treatment of depression is characterized in that, it is by following weight portion
Chinese medicinal raw materials is made:
Arillus Longan 10-14 weight portion
Semen Ziziphi Spinosae (parched) 10-14 weight portion
Radix Polygalae 8-12 weight portion
Semen Platycladi 8-12 weight portion
Radix Glycyrrhizae Preparata 3-7 weight portion
Radix Ginseng 8-12 weight portion
Radix Astragali 10-14 weight portion
Poria 13-17 weight portion
Rhizoma Atractylodis Macrocephalae 10-14 weight portion
Radix Angelicae Sinensis 8-122 weight portion.
2, Chinese medicine preparation according to claim 1 is characterized in that: described Chinese medicine preparation is a said dosage form on any materia medica.
3, Chinese medicine preparation according to claim 2 is characterized in that: described dosage form is a capsule, tablet, granule, oral liquid, pill, powder, sublimed preparation, any pharmaceutical dosage form in the unguentum.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910084301A CN101653504A (en) | 2009-05-20 | 2009-05-20 | Traditional Chinese medicine for treating depression |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910084301A CN101653504A (en) | 2009-05-20 | 2009-05-20 | Traditional Chinese medicine for treating depression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101653504A true CN101653504A (en) | 2010-02-24 |
Family
ID=41708104
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200910084301A Pending CN101653504A (en) | 2009-05-20 | 2009-05-20 | Traditional Chinese medicine for treating depression |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101653504A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102100745A (en) * | 2011-01-21 | 2011-06-22 | 王静怡 | Oral administration medicament for treating depression |
| CN103127286A (en) * | 2011-12-05 | 2013-06-05 | 鲍力恒 | Medicine component used for curing or lightening melancholia or neurodegeneration disease |
| CN105148100A (en) * | 2015-10-27 | 2015-12-16 | 程宝英 | Nursing capsules for treating postpartum depression and preparation method thereof |
| CN105920382A (en) * | 2016-04-22 | 2016-09-07 | 鹿哲维 | Traditional Chinese medicinal composition for treating heart-spleen deficiency type reactive depression |
| CN106540182A (en) * | 2017-01-12 | 2017-03-29 | 张超英 | A kind of Chinese medicine of regulating mental state |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1823992A (en) * | 2005-12-15 | 2006-08-30 | 北京阜康仁生物制药科技有限公司 | Ginseny spleen invigorating preparation and its new preparation method |
-
2009
- 2009-05-20 CN CN200910084301A patent/CN101653504A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1823992A (en) * | 2005-12-15 | 2006-08-30 | 北京阜康仁生物制药科技有限公司 | Ginseny spleen invigorating preparation and its new preparation method |
Non-Patent Citations (1)
| Title |
|---|
| 李清亚,王晓慧,宋瑞华: "中西医结合治疗中风后抑郁症", 《现代中西医结合杂志》 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102100745A (en) * | 2011-01-21 | 2011-06-22 | 王静怡 | Oral administration medicament for treating depression |
| CN103127286A (en) * | 2011-12-05 | 2013-06-05 | 鲍力恒 | Medicine component used for curing or lightening melancholia or neurodegeneration disease |
| CN105148100A (en) * | 2015-10-27 | 2015-12-16 | 程宝英 | Nursing capsules for treating postpartum depression and preparation method thereof |
| CN105920382A (en) * | 2016-04-22 | 2016-09-07 | 鹿哲维 | Traditional Chinese medicinal composition for treating heart-spleen deficiency type reactive depression |
| CN106540182A (en) * | 2017-01-12 | 2017-03-29 | 张超英 | A kind of Chinese medicine of regulating mental state |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1994451B (en) | Chinese medicinal composition for treating depression, its preparation method and application | |
| CN102198241B (en) | Medicine for alleviating nervousness and taking care of sub-health | |
| CN102813839B (en) | Compound medicine for treating cluster headache syndrome | |
| CN101711847B (en) | Oral traditional Chinese medicine preparation for treating melancholia and anxiety neurosis | |
| CN101653504A (en) | Traditional Chinese medicine for treating depression | |
| CN108653571A (en) | A kind of drug and preparation method thereof improving sleep | |
| CN105327287A (en) | Pharmaceutical composition for treating psychosis and preparation technology thereof | |
| CN101658659A (en) | Chinese herba preparation for treating anxiety disorder | |
| CN105769789A (en) | Clozapine tablets for treating schizophrenia and preparation method thereof | |
| CN103405719A (en) | Medicament for treatment of depression | |
| WO2017152655A1 (en) | Traditional chinese medicine preparation for treating qi and blood deficiency-type generalized anxiety disorder | |
| CN107334952B (en) | Ear acupoint sticking and acupuncture combined traditional Chinese medicine for treating phlegm-dampness accumulation type primary hypertension and application thereof | |
| CN101732484A (en) | Capsule for restoring vital energy and producing blood | |
| CN101658573A (en) | Chinese herba preparation for treating depression | |
| CN104383420A (en) | Preparation method of pharmaceutical preparation for treating insomnia and dreaminess | |
| CN104383421A (en) | Pharmaceutical preparation for treating insomnia and dreaminess | |
| CN103877376B (en) | A kind of pharmaceutical preparation treating depression | |
| CN101653573A (en) | Traditional Chinese medicine preparation for treating insomnia | |
| CN108143929B (en) | Medicine for treating vascular dementia | |
| CN106581299B (en) | Traditional Chinese medicine composition for improving kidney qi deficiency of middle-aged and old people and application thereof | |
| CN102716260B (en) | Medicine for fast improving sperm quality and sexual function | |
| CN104705634A (en) | Lucid ganoderma healthcare product for protecting health | |
| CN102526612B (en) | Traditional Chinese medicine composite for curing angina pectoris | |
| CN102579831A (en) | Immunotherapy of treating cancer through snuffing and steaming traditional Chinese medicine | |
| CN103263595A (en) | Traditional Chinese medicine composition for treating diabetes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20100224 |